"Adjuvant atezolizumab improved survival outcomes in patients with muscle-invasive bladder cancer who had no radiographic disease but had detectable circulating tumor DNA in their blood. Muscle-invasive bladder cancer is an aggressive disease generally treated with cystectomy with or without neoadjuvant therapy."
"Following curative-intent surgery, about 50% of patients develop recurrence, but evidence of survival benefits with adjuvant treatment is lacking. Liquid biopsy approaches involving the detection of circulating tumor DNA (ctDNA) have been proposed to select patients who could benefit from adjuvant treatment while avoiding overtreatment in those at low risk of recurrence."
Adjuvant atezolizumab improved survival in patients with muscle-invasive bladder cancer who lacked radiographic disease but had detectable circulating tumor DNA (ctDNA). Muscle-invasive bladder cancer is an aggressive disease generally treated with cystectomy with or without neoadjuvant therapy. About 50% of patients develop recurrence after curative-intent surgery, and clear evidence of survival benefit from adjuvant treatment has been lacking. Detection of ctDNA by liquid biopsy can identify minimal residual disease and stratify patients by recurrence risk. Using ctDNA to select patients for adjuvant atezolizumab could concentrate benefit on high-risk individuals while avoiding overtreatment of low-risk patients.
Read at Nature
Unable to calculate read time
Collection
[
|
...
]